source
- Compass Therapeutics to file BLA for tovecimig despite FDA call for new trialCompass Therapeutics announced it will continue pursuing a biologics license application (BLA) for its bispecific antibody tovecimig aimed at advanced biliary tract cancer, even after the FDA sugge…
- Novo Nordisk cuts 13,000 jobs to redirect funds toward R&DNovo Nordisk announced further workforce reductions, bringing total departures to about 13,000 over the past year. CEO Maziar Mike Doustdar said the cuts are intended to free up capital for resear…